There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ – Research Report), Aurinia Pharmaceuticals (AUPH – Research Report) and POINT Biopharma Global (PNT – Research Report) with bullish sentiments.
Johnson & Johnson (JNJ)
In a report issued on January 25, David Risinger from SVB Securities maintained a Buy rating on Johnson & Johnson, with a price target of $186.00. The company’s shares closed last Thursday at $168.89.
According to TipRanks.com, Risinger is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $185.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Aurinia Pharmaceuticals (AUPH)
SVB Securities analyst Joseph Schwartz maintained a Buy rating on Aurinia Pharmaceuticals on January 25. The company’s shares closed last Thursday at $9.21.
According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Aurinia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $11.83, a 28.2% upside from current levels. In a report issued on January 25, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target.
POINT Biopharma Global (PNT)
SVB Securities analyst Faisal Khurshid reiterated a Buy rating on POINT Biopharma Global on January 25. The company’s shares closed last Thursday at $7.22.
Khurshid has an average return of
According to TipRanks.com, Khurshid is ranked #4604 out of 8298 analysts.
Currently, the analyst consensus on POINT Biopharma Global is a Strong Buy with an average price target of $17.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on JNJ:
- J&J conference call comments ‘a good sign’ for Protagonist, says JMP Securities
- Johnson & Johnson Reports Earnings: Did it Beat Estimate Forecasts?
- Johnson & Johnson says assuming a lot of inflationary carryover in 2023
- Johnson & Johnson sees ‘above market growth’ in Pharmaceutical segment in FY23
- Johnson & Johnson expects FY23 OPEX leverage offset by inflationary pressures